Research ExplorerPublicationsRisk for Pelvic Metastasis and Role of Pelvic Lymphadenectom...

Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study

Standard

Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study. / Woelber, Linn; Hampl, Monika; Eulenburg, Christine Zu; Prieske, Katharina; Hambrecht, Johanna; Fuerst, Sophie; Klapdor, Ruediger; Heublein, Sabine; Gass, Paul; Rohner, Annika; Canzler, Ulrich; Becker, Sven; Bommert, Mareike; Bauerschlag, Dirk; Denecke, Agnieszka; Hanker, Lars; Runnebaumn, Ingo; Forner, Dirk M; Schochter, Fabienne; Klar, Maximilian; Schwab, Roxana; Koepke, Melitta; Kalder, Matthias; Hantschmann, Peer; Ratiu, Dominik; Denschlag, Dominik; Schroeder, Willibald; Tuschy, Benjamin; Baumann, Klaus; Mustea, Alexander; Soergel, Philipp; Bronger, Holger; Bauerschmitz, Gerd; Kosse, Jens; Koch, Martin C; Ignatov, Atanas; Sehouli, Jalid; Dannecker, Christian; Mahner, Sven; Jaeger, Anna.

In: CANCERS, Vol. 14, No. 2, 418, 14.01.2022.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Woelber, L, Hampl, M, Eulenburg, CZ, Prieske, K, Hambrecht, J, Fuerst, S, Klapdor, R, Heublein, S, Gass, P, Rohner, A, Canzler, U, Becker, S, Bommert, M, Bauerschlag, D, Denecke, A, Hanker, L, Runnebaumn, I, Forner, DM, Schochter, F, Klar, M, Schwab, R, Koepke, M, Kalder, M, Hantschmann, P, Ratiu, D, Denschlag, D, Schroeder, W, Tuschy, B, Baumann, K, Mustea, A, Soergel, P, Bronger, H, Bauerschmitz, G, Kosse, J, Koch, MC, Ignatov, A, Sehouli, J, Dannecker, C, Mahner, S & Jaeger, A 2022, 'Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study', CANCERS, vol. 14, no. 2, 418. https://doi.org/10.3390/cancers14020418

APA

Woelber, L., Hampl, M., Eulenburg, C. Z., Prieske, K., Hambrecht, J., Fuerst, S., Klapdor, R., Heublein, S., Gass, P., Rohner, A., Canzler, U., Becker, S., Bommert, M., Bauerschlag, D., Denecke, A., Hanker, L., Runnebaumn, I., Forner, D. M., Schochter, F., ... Jaeger, A. (2022). Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study. CANCERS, 14(2), [418]. https://doi.org/10.3390/cancers14020418

Vancouver

Woelber L, Hampl M, Eulenburg CZ, Prieske K, Hambrecht J, Fuerst S et al. Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study. CANCERS. 2022 Jan 14;14(2). 418. https://doi.org/10.3390/cancers14020418

Bibtex

@article{eca5e026949b47df95f9a5f84d5a3a07,
title = "Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study",
abstract = "The need for pelvic treatment in patients with node-positive vulvar cancer (VSCC) and the value of pelvic lymphadenectomy (LAE) as a staging procedure to plan adjuvant radiotherapy (RT) is controversial. In this retrospective, multicenter analysis, 306 patients with primary node-positive VSCC treated at 33 gynecologic oncology centers in Germany between 2017 and 2019 were analyzed. All patients received surgical staging of the groins; nodal status was as follows: 23.9% (73/306) pN1a, 23.5% (72/306) pN1b, 20.4% (62/306) pN2a/b, and 31.9% (97/306) pN2c/pN3. A total of 35.6% (109/306) received pelvic LAE; pelvic nodal involvement was observed in 18.5%. None of the patients with nodal status pN1a or pN1b and pelvic LAE showed pelvic nodal involvement. Taking only patients with nodal status ≥pN2a into account, the rate of pelvic involvement was 25%. In total, adjuvant RT was applied in 64.4% (197/306). Only half of the pelvic node-positive (N+) patients received adjuvant RT to the pelvis (50%, 10/20 patients); 41.9% (122/291 patients) experienced recurrent disease or died. In patients with histologically-confirmed pelvic metastases after LAE, distant recurrences were most frequently observed (7/20 recurrences). Conclusions: A relevant risk regarding pelvic nodal involvement was observed from nodal status pN2a and higher. Our data support the omission of pelvic treatment in patients with nodal status pN1a and pN1b.",
author = "Linn Woelber and Monika Hampl and Eulenburg, {Christine Zu} and Katharina Prieske and Johanna Hambrecht and Sophie Fuerst and Ruediger Klapdor and Sabine Heublein and Paul Gass and Annika Rohner and Ulrich Canzler and Sven Becker and Mareike Bommert and Dirk Bauerschlag and Agnieszka Denecke and Lars Hanker and Ingo Runnebaumn and Forner, {Dirk M} and Fabienne Schochter and Maximilian Klar and Roxana Schwab and Melitta Koepke and Matthias Kalder and Peer Hantschmann and Dominik Ratiu and Dominik Denschlag and Willibald Schroeder and Benjamin Tuschy and Klaus Baumann and Alexander Mustea and Philipp Soergel and Holger Bronger and Gerd Bauerschmitz and Jens Kosse and Koch, {Martin C} and Atanas Ignatov and Jalid Sehouli and Christian Dannecker and Sven Mahner and Anna Jaeger",
year = "2022",
month = jan,
day = "14",
doi = "10.3390/cancers14020418",
language = "English",
volume = "14",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

RIS

TY - JOUR

T1 - Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study

AU - Woelber, Linn

AU - Hampl, Monika

AU - Eulenburg, Christine Zu

AU - Prieske, Katharina

AU - Hambrecht, Johanna

AU - Fuerst, Sophie

AU - Klapdor, Ruediger

AU - Heublein, Sabine

AU - Gass, Paul

AU - Rohner, Annika

AU - Canzler, Ulrich

AU - Becker, Sven

AU - Bommert, Mareike

AU - Bauerschlag, Dirk

AU - Denecke, Agnieszka

AU - Hanker, Lars

AU - Runnebaumn, Ingo

AU - Forner, Dirk M

AU - Schochter, Fabienne

AU - Klar, Maximilian

AU - Schwab, Roxana

AU - Koepke, Melitta

AU - Kalder, Matthias

AU - Hantschmann, Peer

AU - Ratiu, Dominik

AU - Denschlag, Dominik

AU - Schroeder, Willibald

AU - Tuschy, Benjamin

AU - Baumann, Klaus

AU - Mustea, Alexander

AU - Soergel, Philipp

AU - Bronger, Holger

AU - Bauerschmitz, Gerd

AU - Kosse, Jens

AU - Koch, Martin C

AU - Ignatov, Atanas

AU - Sehouli, Jalid

AU - Dannecker, Christian

AU - Mahner, Sven

AU - Jaeger, Anna

PY - 2022/1/14

Y1 - 2022/1/14

N2 - The need for pelvic treatment in patients with node-positive vulvar cancer (VSCC) and the value of pelvic lymphadenectomy (LAE) as a staging procedure to plan adjuvant radiotherapy (RT) is controversial. In this retrospective, multicenter analysis, 306 patients with primary node-positive VSCC treated at 33 gynecologic oncology centers in Germany between 2017 and 2019 were analyzed. All patients received surgical staging of the groins; nodal status was as follows: 23.9% (73/306) pN1a, 23.5% (72/306) pN1b, 20.4% (62/306) pN2a/b, and 31.9% (97/306) pN2c/pN3. A total of 35.6% (109/306) received pelvic LAE; pelvic nodal involvement was observed in 18.5%. None of the patients with nodal status pN1a or pN1b and pelvic LAE showed pelvic nodal involvement. Taking only patients with nodal status ≥pN2a into account, the rate of pelvic involvement was 25%. In total, adjuvant RT was applied in 64.4% (197/306). Only half of the pelvic node-positive (N+) patients received adjuvant RT to the pelvis (50%, 10/20 patients); 41.9% (122/291 patients) experienced recurrent disease or died. In patients with histologically-confirmed pelvic metastases after LAE, distant recurrences were most frequently observed (7/20 recurrences). Conclusions: A relevant risk regarding pelvic nodal involvement was observed from nodal status pN2a and higher. Our data support the omission of pelvic treatment in patients with nodal status pN1a and pN1b.

AB - The need for pelvic treatment in patients with node-positive vulvar cancer (VSCC) and the value of pelvic lymphadenectomy (LAE) as a staging procedure to plan adjuvant radiotherapy (RT) is controversial. In this retrospective, multicenter analysis, 306 patients with primary node-positive VSCC treated at 33 gynecologic oncology centers in Germany between 2017 and 2019 were analyzed. All patients received surgical staging of the groins; nodal status was as follows: 23.9% (73/306) pN1a, 23.5% (72/306) pN1b, 20.4% (62/306) pN2a/b, and 31.9% (97/306) pN2c/pN3. A total of 35.6% (109/306) received pelvic LAE; pelvic nodal involvement was observed in 18.5%. None of the patients with nodal status pN1a or pN1b and pelvic LAE showed pelvic nodal involvement. Taking only patients with nodal status ≥pN2a into account, the rate of pelvic involvement was 25%. In total, adjuvant RT was applied in 64.4% (197/306). Only half of the pelvic node-positive (N+) patients received adjuvant RT to the pelvis (50%, 10/20 patients); 41.9% (122/291 patients) experienced recurrent disease or died. In patients with histologically-confirmed pelvic metastases after LAE, distant recurrences were most frequently observed (7/20 recurrences). Conclusions: A relevant risk regarding pelvic nodal involvement was observed from nodal status pN2a and higher. Our data support the omission of pelvic treatment in patients with nodal status pN1a and pN1b.

U2 - 10.3390/cancers14020418

DO - 10.3390/cancers14020418

M3 - SCORING: Journal article

C2 - 35053582

VL - 14

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 2

M1 - 418

ER -